Genetic breakthrough drug enters human trials for silent liver killer
Disease control
Ongoing
This study is testing an experimental drug called VSA006 in Chinese adults with nonalcoholic steatohepatitis (NASH), a serious form of fatty liver disease. The drug works by targeting a specific liver protein linked to disease progression. Researchers will check if the injection …
Phase: PHASE2 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC